Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211122402> ?p ?o ?g. }
- W4211122402 abstract "Background Anti‐leukotrienes agents are currently being studied as alternative first line agents to inhaled corticosteroids in mild to moderate chronic asthma. Objectives To compare the safety and efficacy of anti‐leukotriene agents with inhaled glucocorticoids (ICS) and to determine the dose‐equivalence of anti‐leukotrienes to daily dose of ICS. Search methods We searched MEDLINE (1966 to Aug 2003), EMBASE (1980 to Aug 2003), CINAHL (1982 to Aug 2003), the Cochrane Airways Group trials register, and the Cochrane Central Register of Controlled Trials (August 2003), abstract books, and reference lists of review articles and trials. We contacted colleagues and international headquarters of anti‐leukotrienes producers. Selection criteria Randomised controlled trials that compared anti‐leukotrienes with inhaled corticosteroids during a minimal 30‐day intervention period in asthmatic patients aged 2 years and older. Data collection and analysis Two reviewers independently assessed the methodological quality or trials and extracted trial data. The primary outcome was the rate of exacerbations requiring systemic corticosteroids. Secondary outcomes included lung function, indices of chronic asthma control, adverse effects and withdrawal rates. Main results 27 trials (including 1 trial testing two protocols) met the inclusion criteria; 13 were of high methodological quality; 20 are published in full‐text. All trials pertained to patients with mild to moderate persistent asthma. Only 3 trials focused on children and adolescents. Trial duration varied from 4 to 37 weeks. In most trials, daily dose of ICS was 400 mcg of beclomethasone or equivalent. Patients treated with anti‐leukotrienes were 65% more likely to suffer an exacerbation requiring systemic steroids [Relative Risk 1.65; 95% Confidence Interval (CI) 1.36 to 2.00]. Twenty six (95% CI: 17 to 47) patients must be treated with anti‐leukotrienes instead of inhaled corticosteroids to cause one extra exacerbation. Significant differences favouring ICS were noted in secondary outcomes where the improvement in FEV1 reached 130 mL [13 trials; 95% CI: 50, 140 mL ]. Other significant benefits of ICS were seen for symptoms, nocturnal awakenings, rescue medication use, symptom‐free days, and quality of life. Anti‐leukotriene therapy was associated with 160% increased risk of withdrawals due to poor asthma control. Twenty nine (95% CI 20 to 48) patients must be treated with anti‐leukotrienes instead of inhaled corticosteroids to cause one extra withdrawal due to poor control . Risk of side effects was not different between groups. Authors' conclusions Inhaled steroids at a dose of 400 mcg/day of beclomethasone or equivalent are more effective than anti‐leukotriene agents given in the usual licensed doses. The exact dose‐equivalence of anti‐leukotriene agents in mcg of ICS remains to be determined. Inhaled glucocorticoids should remain the first line monotherapy for persistent asthma." @default.
- W4211122402 created "2022-02-13" @default.
- W4211122402 creator A5063247630 @default.
- W4211122402 creator A5065533338 @default.
- W4211122402 date "2004-01-26" @default.
- W4211122402 modified "2023-09-30" @default.
- W4211122402 title "Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children" @default.
- W4211122402 cites W1576173198 @default.
- W4211122402 cites W1595184853 @default.
- W4211122402 cites W1909409123 @default.
- W4211122402 cites W1965778637 @default.
- W4211122402 cites W1966146541 @default.
- W4211122402 cites W1968660451 @default.
- W4211122402 cites W1972351481 @default.
- W4211122402 cites W1974121972 @default.
- W4211122402 cites W1975272363 @default.
- W4211122402 cites W1975315932 @default.
- W4211122402 cites W1976011139 @default.
- W4211122402 cites W1979096132 @default.
- W4211122402 cites W1979358858 @default.
- W4211122402 cites W1982269964 @default.
- W4211122402 cites W1984849285 @default.
- W4211122402 cites W1985400158 @default.
- W4211122402 cites W1986235865 @default.
- W4211122402 cites W1986555896 @default.
- W4211122402 cites W1987343787 @default.
- W4211122402 cites W1988895307 @default.
- W4211122402 cites W1989350620 @default.
- W4211122402 cites W1991819079 @default.
- W4211122402 cites W1991857563 @default.
- W4211122402 cites W1996982788 @default.
- W4211122402 cites W1998903070 @default.
- W4211122402 cites W2006436081 @default.
- W4211122402 cites W2007567016 @default.
- W4211122402 cites W2008620220 @default.
- W4211122402 cites W2009807650 @default.
- W4211122402 cites W2011818405 @default.
- W4211122402 cites W2014619371 @default.
- W4211122402 cites W2015283837 @default.
- W4211122402 cites W2016413781 @default.
- W4211122402 cites W2017805361 @default.
- W4211122402 cites W2019672870 @default.
- W4211122402 cites W2020716977 @default.
- W4211122402 cites W2022010133 @default.
- W4211122402 cites W2025604754 @default.
- W4211122402 cites W2028836971 @default.
- W4211122402 cites W2032470063 @default.
- W4211122402 cites W2032637466 @default.
- W4211122402 cites W2033216394 @default.
- W4211122402 cites W2033984690 @default.
- W4211122402 cites W2037971296 @default.
- W4211122402 cites W2039340152 @default.
- W4211122402 cites W2041017243 @default.
- W4211122402 cites W2041812679 @default.
- W4211122402 cites W2045303196 @default.
- W4211122402 cites W2045968934 @default.
- W4211122402 cites W2046542895 @default.
- W4211122402 cites W2046741566 @default.
- W4211122402 cites W2049114017 @default.
- W4211122402 cites W2051554235 @default.
- W4211122402 cites W2051656004 @default.
- W4211122402 cites W2054604027 @default.
- W4211122402 cites W2059776008 @default.
- W4211122402 cites W2060862766 @default.
- W4211122402 cites W2061801795 @default.
- W4211122402 cites W2065283934 @default.
- W4211122402 cites W2067568803 @default.
- W4211122402 cites W2069233429 @default.
- W4211122402 cites W2070331767 @default.
- W4211122402 cites W2073802634 @default.
- W4211122402 cites W2073817403 @default.
- W4211122402 cites W2077107378 @default.
- W4211122402 cites W2078618680 @default.
- W4211122402 cites W2079788509 @default.
- W4211122402 cites W2082695270 @default.
- W4211122402 cites W2083950184 @default.
- W4211122402 cites W2084414591 @default.
- W4211122402 cites W2087019177 @default.
- W4211122402 cites W2087410653 @default.
- W4211122402 cites W2089078886 @default.
- W4211122402 cites W2090477973 @default.
- W4211122402 cites W2091177973 @default.
- W4211122402 cites W2098698630 @default.
- W4211122402 cites W2099364430 @default.
- W4211122402 cites W2099665268 @default.
- W4211122402 cites W2100910563 @default.
- W4211122402 cites W2103194450 @default.
- W4211122402 cites W2103925866 @default.
- W4211122402 cites W2104263441 @default.
- W4211122402 cites W2104505088 @default.
- W4211122402 cites W2105573753 @default.
- W4211122402 cites W2108178724 @default.
- W4211122402 cites W2109306397 @default.
- W4211122402 cites W2111077997 @default.
- W4211122402 cites W2116204260 @default.
- W4211122402 cites W2118378443 @default.
- W4211122402 cites W2118991338 @default.
- W4211122402 cites W2120012059 @default.
- W4211122402 cites W2121416572 @default.
- W4211122402 cites W2121906493 @default.